New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impair ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...

Pending FDA feedback, the Company will also seek FDA orphan drug designation (“ODD”) and NDA marketing ... however 3 to 5% of patients cannot tolerate allopurinol. An alternative XOI, Febuxostat, ...

The goal of treatment is to reduce levels of uric acid in the blood below the 6 mg/dl threshold, but in some cases, current drugs like allopurinol and febuxostat aren’t able to achieve that ...

Sometimes, they may prescribe a drug such as allopurinol (Zyloprim) or febuxostat (Uloric) to lower your uric acid levels. Your doctor will decide whether it’s safe for you to continue taking ...

Methods The phase IIa, open-label, multicentre study randomised 64 subjects into one of five cohorts to receive febuxostat (40 or 80 mg) alone or in combination with verinurad 2.5–20 mg. Serial plasma ...

In propensity-matched analyses, febuxostat did not significantly differ from allopurinol; HR for HSRs was 1.25 (95% CI: 0.93 to 1.67). Compared with allopurinol start dose <200 mg/day, allopurinol ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...